AR035564A1 - Moduladores selectivos de receptores de estrogenos en combinacion con estrogenos - Google Patents
Moduladores selectivos de receptores de estrogenos en combinacion con estrogenosInfo
- Publication number
- AR035564A1 AR035564A1 ARP010100372A ARP010100372A AR035564A1 AR 035564 A1 AR035564 A1 AR 035564A1 AR P010100372 A ARP010100372 A AR P010100372A AR P010100372 A ARP010100372 A AR P010100372A AR 035564 A1 AR035564 A1 AR 035564A1
- Authority
- AR
- Argentina
- Prior art keywords
- administration
- strogens
- strogen
- receivers
- combination
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/30—Oestrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Physical Education & Sports Medicine (AREA)
- Neurology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Rheumatology (AREA)
- Vascular Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Psychiatry (AREA)
- Cardiology (AREA)
- Child & Adolescent Psychology (AREA)
- Reproductive Health (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Métodos novedosos para reducir o eliminar la incidencia de accesos de calor y síntomas menopáusicos, que al mismo tiempo disminuyen el riesgo de adquirir cáncer de mama o de endometrio y para tratar y/o inhibir además el desarrollo de osteoporosis, hipercolesterolemia, hiperlipidemia, ateroesclerosis, hipertensión, resistencia a insulina, diabetes, pérdida de masa muscular, obesidad, irregularidades menstruales, enfermedad de Alzheimer o sequedad vaginal en animales de sangre caliente susceptibles, inclusive seres humanos que comprende la administración de un modulador selectivo de receptores de estrógeno, en particular compuestos que presentan la estructura general (1) y una cantidad de un estrógeno o un compuesto estrogénico / androgénico mixto. Además, se describe específicamente la administración de bifosfonatos, progestágeno o un precursor de esteroides sexuales para el tratamiento médico y/o la inhibición de algunas de las enfermedades mencionadas anteriormente. También se describen composiciones farmacéuticas para la distribución del o de los ingredientes activos y uno o varios conjuntos de elementos (''kits'') de utilidad para la presente.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US17860100P | 2000-01-28 | 2000-01-28 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR035564A1 true AR035564A1 (es) | 2004-06-16 |
Family
ID=22653187
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP010100372A AR035564A1 (es) | 2000-01-28 | 2001-01-26 | Moduladores selectivos de receptores de estrogenos en combinacion con estrogenos |
Country Status (21)
Country | Link |
---|---|
US (3) | US20020198179A1 (es) |
EP (1) | EP1251855A1 (es) |
JP (1) | JP2003520817A (es) |
KR (1) | KR20020073566A (es) |
CN (1) | CN1400904A (es) |
AR (1) | AR035564A1 (es) |
AU (1) | AU2991301A (es) |
BR (1) | BR0108107A (es) |
CA (1) | CA2395730A1 (es) |
CZ (1) | CZ20022401A3 (es) |
HK (1) | HK1048761A1 (es) |
HU (1) | HUP0204211A3 (es) |
IL (1) | IL149990A0 (es) |
MX (1) | MXPA02007165A (es) |
NO (1) | NO20023484D0 (es) |
NZ (1) | NZ534348A (es) |
PL (1) | PL357163A1 (es) |
RU (1) | RU2342145C2 (es) |
SK (1) | SK9592002A3 (es) |
WO (1) | WO2001054699A1 (es) |
ZA (1) | ZA200205926B (es) |
Families Citing this family (71)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2234060A1 (en) * | 1995-10-06 | 1997-04-10 | Arch Development Corporation | Methods and compositions for viral enhancement of cell killing |
JP2004502734A (ja) * | 2000-07-06 | 2004-01-29 | ワイス | 一酸化窒素シンターゼ活性の増強方法 |
AU2001273144A1 (en) * | 2000-07-06 | 2002-01-21 | Wyeth | Use of substituted indole compounds for treating neuropeptide y-related conditions |
US6245819B1 (en) | 2000-07-21 | 2001-06-12 | Hormos Medical Oy, Ltd. | Method for the treatment of vaginal dryness and sexual dysfunction in women during or after the menopause |
US6503894B1 (en) | 2000-08-30 | 2003-01-07 | Unimed Pharmaceuticals, Inc. | Pharmaceutical composition and method for treating hypogonadism |
IL145838A (en) * | 2000-10-16 | 2008-11-03 | Pfizer Prod Inc | Use of an estrogen agonist / antagonist to produce a drug for the treatment of vaginitis |
KR20030048026A (ko) * | 2001-07-06 | 2003-06-18 | 펜웨스트 파머슈티칼즈 컴파니 | 옥시모르폰의 서방형 제제 |
CN1599606A (zh) | 2001-07-31 | 2005-03-23 | 辉瑞产品公司 | 包含***激动剂/拮抗剂、***与孕激素组合的药物组合物、试剂盒和方法 |
US20080249183A1 (en) * | 2001-11-29 | 2008-10-09 | Steiner Mitchell S | Treatment of androgen-deprivation induced osteoporosis |
US20060269611A1 (en) * | 2001-11-29 | 2006-11-30 | Steiner Mitchell S | Prevention and treatment of androgen-deprivation induced osteoporosis |
US20040214898A1 (en) * | 2001-11-29 | 2004-10-28 | Steiner Mitchell S. | Methods for treating hot flashes |
US20070197664A1 (en) * | 2001-11-29 | 2007-08-23 | Steiner Mitchell S | Prevention and treatment of androgen-deprivation induced osteoporosis |
US20050080143A1 (en) * | 2001-11-29 | 2005-04-14 | Steiner Mitchell S. | Treatment of androgen-deprivation induced osteoporosis |
TW200307553A (en) * | 2002-05-24 | 2003-12-16 | Akzo Nobel Nv | Treatment of post-menopausal complaints in breast cancer patients |
PT1509215E (pt) * | 2002-06-06 | 2007-01-31 | Hormos Medical Ltd | Tratamento ou profilaxia da atrofia urogenital e seus sintomas em mulheres |
KR20060028822A (ko) * | 2003-05-23 | 2006-04-03 | 엔.브이. 오가논 | 다형성 티볼론을 포함하는 즉시-방출형 약학 제형 |
EP1713770A1 (en) * | 2004-01-29 | 2006-10-25 | Eli Lilly And Company | Selective estrogen receptor modulators |
US8080675B2 (en) | 2004-09-21 | 2011-12-20 | Marshall Edwards, Inc. | Chroman derivatives, medicaments and use in therapy |
CN101056868B (zh) | 2004-09-21 | 2012-05-02 | 马休爱德华兹股份有限公司 | 取代的苯并二氢吡喃衍生物、药物及其在治疗中的应用 |
CN102357248A (zh) | 2004-10-20 | 2012-02-22 | 恩多研究公司 | 单独的性甾体前体或与选择性***受体调节剂联合用于防治绝经后女性的***疾病和病症 |
JP2008530210A (ja) * | 2005-02-16 | 2008-08-07 | ワイス | 放射線または化学療法誘発粘膜炎および放射線膀胱炎のためのエストロゲン受容体−β選択性アゴニストの使用 |
BRPI0711525A2 (pt) | 2006-06-02 | 2011-11-01 | Pear Tree Women S Health Care | composição farmacêutica e método para tratar sintomas de vaginite atrófica |
EP2037905B1 (en) * | 2006-06-23 | 2013-05-01 | Radius Health, Inc. | Treatment of vasomotor symptoms with selective estrogen receptor modulators |
WO2008101030A1 (en) * | 2007-02-13 | 2008-08-21 | The Regents Of The University Of California | Methods for amplifying steroid hormone effects |
US7504530B2 (en) | 2007-02-14 | 2009-03-17 | Hormos Medical Ltd. | Methods for the preparation of fispemifene from ospemifene |
PL2121553T3 (pl) | 2007-02-14 | 2012-11-30 | Hormos Medical Ltd | Sposób wytwarzania cennych terapeutycznie pochodnych trifenylobutenu |
US8268806B2 (en) | 2007-08-10 | 2012-09-18 | Endorecherche, Inc. | Pharmaceutical compositions |
US20140040862A1 (en) * | 2008-04-03 | 2014-02-06 | Adobe Systems Incorporated | Copying Reusable Components from a Remote Source |
AU2016235019B2 (en) * | 2009-06-16 | 2018-06-28 | Endorecherche, Inc. | Treatment of alzheimer's disease, loss of cognition, memory loss, and dementia with sex steroid precursors in combination with selective estrogen receptor modulators |
AU2014201406B2 (en) * | 2009-06-16 | 2016-08-11 | Endorecherche, Inc. | Treatment of hot flushes, vasomotor symptoms, and night sweats with sex steroid precursors in combination with selective estrogen receptor modulators |
US20100317635A1 (en) | 2009-06-16 | 2010-12-16 | Endorecherche, Inc. | Treatment of hot flushes, vasomotor symptoms, and night sweats with sex steroid precursors in combination with selective estrogen receptor modulators |
WO2011143469A1 (en) | 2010-05-12 | 2011-11-17 | Radius Health,Inc | Therapeutic regimens |
EP3205648A1 (en) | 2010-06-10 | 2017-08-16 | Seragon Pharmaceuticals, Inc. | Estrogen receptor modulators and uses thereof |
WO2011159769A2 (en) | 2010-06-17 | 2011-12-22 | Aragon Pharmaceuticals, Inc. | Indane estrogen receptor modulators and uses thereof |
JP6013349B2 (ja) | 2010-11-01 | 2016-10-25 | メイ ファーマ, インク.Mei Pharma, Inc. | 癌の処置のためのイソフラボノイド化合物および方法 |
UA113291C2 (xx) | 2011-08-04 | 2017-01-10 | Метаболіти транскломіфену і їх застосування | |
US9301920B2 (en) | 2012-06-18 | 2016-04-05 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
PT2782584T (pt) | 2011-11-23 | 2021-09-02 | Therapeuticsmd Inc | Preparações e terapias de substituição para hormonoterapias naturais combinadas |
EA029559B1 (ru) | 2011-12-14 | 2018-04-30 | Серагон Фармасьютикалс, Инк. | Фторированные модуляторы рецепторов эстрогенов и их применение |
CA2857061A1 (en) | 2011-12-16 | 2013-06-20 | Olema Pharmaceuticals, Inc. | Novel benzopyran compounds, compositions and uses thereof |
CN102584687A (zh) * | 2011-12-30 | 2012-07-18 | 北京赛林泰医药技术有限公司 | 作为选择性***受体调节剂的乙烯衍生物 |
US9161940B2 (en) * | 2012-02-14 | 2015-10-20 | Repros Therapeutics Inc. | Selective estrogen receptor modulators with short half-lives and uses thereof |
CN102631677A (zh) * | 2012-04-19 | 2012-08-15 | 中国农业大学 | 一种预防和/或治疗动脉粥样硬化的药物组合物 |
US20150196640A1 (en) | 2012-06-18 | 2015-07-16 | Therapeuticsmd, Inc. | Progesterone formulations having a desirable pk profile |
US10806740B2 (en) | 2012-06-18 | 2020-10-20 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
US10806697B2 (en) | 2012-12-21 | 2020-10-20 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US20130338122A1 (en) | 2012-06-18 | 2013-12-19 | Therapeuticsmd, Inc. | Transdermal hormone replacement therapies |
WO2014060639A1 (en) | 2012-10-19 | 2014-04-24 | Fermion Oy | A process for the preparation of ospemifene |
CA2889770A1 (en) | 2012-11-02 | 2014-05-08 | Repros Therapeutics Inc. | Trans-clomiphene for use in cancer therapy |
US9180091B2 (en) | 2012-12-21 | 2015-11-10 | Therapeuticsmd, Inc. | Soluble estradiol capsule for vaginal insertion |
US11246875B2 (en) | 2012-12-21 | 2022-02-15 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US11266661B2 (en) | 2012-12-21 | 2022-03-08 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US10471072B2 (en) | 2012-12-21 | 2019-11-12 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US10568891B2 (en) | 2012-12-21 | 2020-02-25 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US10537581B2 (en) | 2012-12-21 | 2020-01-21 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
WO2014203132A1 (en) | 2013-06-19 | 2014-12-24 | Olema Pharmaceuticals, Inc. | Substituted benzopyran compounds, compositions and uses thereof |
WO2014203129A1 (en) | 2013-06-19 | 2014-12-24 | Olema Pharmaceuticals, Inc. | Combinations of benzopyran compounds, compositions and uses thereof |
US9744177B2 (en) * | 2014-03-10 | 2017-08-29 | Endorecherche, Inc. | Treatment of male androgen deficiency symptoms or diseases with sex steroid precursor combined with SERM |
US9421264B2 (en) | 2014-03-28 | 2016-08-23 | Duke University | Method of treating cancer using selective estrogen receptor modulators |
DK3122426T3 (da) | 2014-03-28 | 2023-04-03 | Univ Duke | Behandling af brystcancer ved anvendelse af selektive østrogenreceptormodulatorer |
RU2016143081A (ru) | 2014-05-22 | 2018-06-26 | Терапьютиксмд, Инк. | Натуральные комбинированные гормонозаместительные составы и терапии |
BR112016029338A2 (pt) | 2014-07-29 | 2017-08-22 | Therapeuticsmd Inc | creme transdérmico |
HUE054998T2 (hu) | 2015-02-02 | 2021-10-28 | Mei Pharma Inc | Kombinációs terápiák emlõrák kezelésében való alkalmazásra |
US10328087B2 (en) | 2015-07-23 | 2019-06-25 | Therapeuticsmd, Inc. | Formulations for solubilizing hormones |
CA3020153A1 (en) | 2016-04-01 | 2017-10-05 | Therapeuticsmd, Inc. | Steroid hormone pharmaceutical composition |
US10286077B2 (en) | 2016-04-01 | 2019-05-14 | Therapeuticsmd, Inc. | Steroid hormone compositions in medium chain oils |
SG10201913951YA (en) | 2016-10-11 | 2020-03-30 | Univ Duke | Lasofoxifene treatment of er+ breast cancer |
MX2019007748A (es) | 2017-01-05 | 2019-09-09 | Radius Pharmaceuticals Inc | Formas polimorficas de rad1901-2hcl. |
US20180207177A1 (en) * | 2017-01-23 | 2018-07-26 | Government Of The United States As Represented By The Secretary Of The Air Force | TREATMENT OF TRIPLE NEGATIVE BREAST CANCER UTILIZING ANDROST-5-ENE-3b,17b-DIOL (b-AED), ANDROST-5-ENE-3b,7b,17b-TRIOL (b-AET) AND ESTRADIOL (E2) |
EP3773524A4 (en) | 2018-04-10 | 2021-12-22 | Duke University | TREATMENT OF BREAST CANCER WITH LASOFOXIFEN |
GB202116903D0 (en) | 2021-11-18 | 2022-01-05 | Sermonix Pharmaceuticals Inc | Lasofoxifene treatment of aromatase-resistant er+ cancer |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5776923A (en) * | 1993-01-19 | 1998-07-07 | Endorecherche, Inc. | Method of treating or preventing osteoporosis by adminstering dehydropiandrosterone |
US5446061A (en) * | 1993-11-05 | 1995-08-29 | Eli Lilly And Company | Methods for lowering serum cholesterol |
US5446071A (en) * | 1994-11-18 | 1995-08-29 | Eli Lilly And Company | Methods for lowering serum cholesterol |
US5897539A (en) * | 1995-09-28 | 1999-04-27 | Schering Aktiengesellschaft | Hormone replacement therapy method and hormone dispenser |
PT802183E (pt) * | 1996-04-19 | 2002-03-28 | American Home Prod | Agentes estrogenicos |
WO1999009007A1 (en) * | 1997-08-21 | 1999-02-25 | American Home Products Corporation | Solid phase synthesis of 2,3-disubstituted indole compounds |
US6465445B1 (en) * | 1998-06-11 | 2002-10-15 | Endorecherche, Inc. | Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors |
US7005428B1 (en) * | 1998-06-11 | 2006-02-28 | Endorecherche, Inc. | Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors |
DE19916419B4 (de) * | 1999-04-08 | 2005-06-16 | Schering Ag | Kombinationspräparat aus Vitamin-D-Metaboliten oder Vitamin-D-Analoga und einem Östrogenpartialagonisten zur Behandlung von Osteoporose |
TR200502284T2 (tr) * | 1999-07-06 | 2005-08-22 | Endorecherche, Inc. | Kilo alımını tedavi ve/veya önleme metotları |
-
2001
- 2001-01-26 CN CN01804028A patent/CN1400904A/zh active Pending
- 2001-01-26 SK SK959-2002A patent/SK9592002A3/sk not_active Application Discontinuation
- 2001-01-26 RU RU2002123047/14A patent/RU2342145C2/ru not_active IP Right Cessation
- 2001-01-26 NZ NZ534348A patent/NZ534348A/en active IP Right Revival
- 2001-01-26 EP EP01902194A patent/EP1251855A1/en not_active Withdrawn
- 2001-01-26 AR ARP010100372A patent/AR035564A1/es unknown
- 2001-01-26 IL IL14999001A patent/IL149990A0/xx unknown
- 2001-01-26 PL PL01357163A patent/PL357163A1/xx not_active Application Discontinuation
- 2001-01-26 JP JP2001554683A patent/JP2003520817A/ja active Pending
- 2001-01-26 AU AU29913/01A patent/AU2991301A/en not_active Abandoned
- 2001-01-26 KR KR1020027009728A patent/KR20020073566A/ko not_active Application Discontinuation
- 2001-01-26 WO PCT/CA2001/000086 patent/WO2001054699A1/en active Application Filing
- 2001-01-26 MX MXPA02007165A patent/MXPA02007165A/es not_active Application Discontinuation
- 2001-01-26 CZ CZ20022401A patent/CZ20022401A3/cs unknown
- 2001-01-26 BR BR0108107-1A patent/BR0108107A/pt not_active Application Discontinuation
- 2001-01-26 HU HU0204211A patent/HUP0204211A3/hu unknown
- 2001-01-26 CA CA002395730A patent/CA2395730A1/en not_active Abandoned
- 2001-11-07 US US10/052,803 patent/US20020198179A1/en not_active Abandoned
- 2001-11-07 US US10/052,824 patent/US20030040510A1/en not_active Abandoned
-
2002
- 2002-05-09 US US10/143,894 patent/US20030065008A1/en not_active Abandoned
- 2002-07-22 NO NO20023484A patent/NO20023484D0/no not_active Application Discontinuation
- 2002-07-24 ZA ZA200005926A patent/ZA200205926B/xx unknown
-
2003
- 2003-02-06 HK HK03100850.6A patent/HK1048761A1/zh unknown
Also Published As
Publication number | Publication date |
---|---|
KR20020073566A (ko) | 2002-09-27 |
CZ20022401A3 (cs) | 2003-10-15 |
CA2395730A1 (en) | 2001-08-02 |
PL357163A1 (en) | 2004-07-26 |
US20020198179A1 (en) | 2002-12-26 |
US20030040510A1 (en) | 2003-02-27 |
MXPA02007165A (es) | 2003-09-22 |
NO20023484L (no) | 2002-07-22 |
NO20023484D0 (no) | 2002-07-22 |
HUP0204211A3 (en) | 2005-06-28 |
US20030065008A1 (en) | 2003-04-03 |
JP2003520817A (ja) | 2003-07-08 |
AU2991301A (en) | 2001-08-07 |
IL149990A0 (en) | 2002-12-01 |
SK9592002A3 (en) | 2003-12-02 |
HK1048761A1 (zh) | 2003-04-17 |
CN1400904A (zh) | 2003-03-05 |
EP1251855A1 (en) | 2002-10-30 |
BR0108107A (pt) | 2003-03-11 |
HUP0204211A2 (hu) | 2003-04-28 |
RU2002123047A (ru) | 2004-03-10 |
NZ534348A (en) | 2006-06-30 |
WO2001054699A1 (en) | 2001-08-02 |
ZA200205926B (en) | 2003-07-24 |
RU2342145C2 (ru) | 2008-12-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR035564A1 (es) | Moduladores selectivos de receptores de estrogenos en combinacion con estrogenos | |
US5719136A (en) | Combination of progesterone antagonists and antiestrogens with partial agonistic action for hormone substitution therapy for perimenopausal and postmenopausal women | |
CA2334702C (en) | Pharmaceutical compositions and uses for androst-5-ene-3.beta.,17.beta.-diol | |
ES2200384T3 (es) | Medio anticonceptivo hormonal. | |
US10201611B2 (en) | Pharmaceutical composition comprising estetrol derivatives for use in cancer therapy | |
US20030004145A1 (en) | Treatment of conditions relating to hormone deficiencies by administration of progestins | |
DE60307602T2 (de) | Kontinuierliche sulfatase-hemmende progestogen enthaltende hormonsubstitutions-therapie | |
BR9911116A (pt) | Processo para tratar ou reduzir o risco de adquirir uma condição selecionada dentre o grupo consistindo de aterosclerose, câncer endometrial, câncer uterino, câncer ovariano, falta de lubrificação vaginal, e perda de massa muscular, composição farmacêutica, e, kit. | |
HU221169B1 (en) | Use of estrogen and antiprogestin for producing pharmaceutical compositions useful in hormon replacement therapy and kit containing the same | |
Judd | Efficacy of transdermal estradiol | |
NZ516502A (en) | Administration of non-oral androgenic steroids to women having an elevated level of sex hormone binding globulin (SHBG) | |
CA2394165A1 (en) | Drospirenone for hormone replacement therapy | |
EP1853272A1 (en) | Compositions of unconjugated estrogens and methods for their use | |
US20120225853A1 (en) | Hormone replacement therapy and depression | |
CZ298402B6 (cs) | Použití farmaceutického prostredku obsahujícího estrogen a nomegestrolacelát | |
Wren et al. | Differential clinical response to oestrogens after menopause | |
Speroff et al. | Practical guidelines for postmenopausal hormone therapy | |
Stevenson | Optimising delivery systems for HRT | |
US9795617B2 (en) | Hormone delivery system and method | |
Holloway | Clinical update on hormone replacement therapy | |
Creatsas | Possible Side-effects of Sexual Hormones | |
Yasar et al. | Effect of misoprostol on bone mineral density in women with postmenopausal osteoporosis | |
MAIDA TAYLOR | Estrogens: Estriol | |
Sismondi et al. | HRT, breast and endometrial cancers: strategies and intervention options | |
RU2201233C1 (ru) | Способ профилактики хронических циститов в период менопаузы |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |